A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Trial Profile

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms STRATOS2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Nov 2017 Primary endpoint has not been met. (Asthma exacerbation rate reduction), according to an AstraZeneca media release.
    • 01 Nov 2017 According to an AstraZeneca media release, full data from the study will be presented at a forthcoming medical meeting.
    • 12 Oct 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top